Brugada's syndrome is one of the main causes of sudden death in young adults 
without a structural heart disease. This is an electrical cardiac illness 
secondary to a mutation of SCN5A gene of chromosome 3 that has a dominant 
autosomic transmission pattern. This mutation implies the dysfunction of the 
sodium channel that increases the Ito, loosing the dome of the epicardiac action 
potential phase two. An "all or none" repolarization pattern ensues and gives 
rise to a phase two reentry. This kind of reentry is responsible for the 
initiation and perpetuation of malignant ventricular arrhythmias among these 
patients. The clinical characteristics of the syndrome are the right bundle 
branch block, ST segment elevation from V1 to V3 leads and sudden death or 
syncope. In some patients, a pharmacological test must be done with ajmaline or 
procainamide to unmask the electrocardiographic changes. At present, the only 
effective treatment is the implantable cardioverter defibrillator (ICD). This 
device has the capability to reduce mortality from 40% annually to 0% at ten 
years. Pharmacological treatment is not useful.